Tetracyclines

Klein, Natalie C.; Cunha, Burke A.

doi:10.1016/s0025-7125(16)30039-6

Cited by 176 publications

(115 citation statements)

References 35 publications

Supporting

Mentioning

113

Contrasting

Unclassified

Order By: Relevance

“…Tetracycline acts by binding to the 30S ribosomal subunit, resulting in the inhibition of protein synthesis (49,50,152,300). A growing number of bacterial species have acquired resistance to the bacteriostatic activity of tetracycline.…”

Section: Mechanisms Of Resistancementioning

confidence: 99%

Molecular Detection of Antimicrobial Resistance

2001

View full text Add to dashboard Cite

The determination of antimicrobial susceptibility of a clinical isolate, especially with increasing resistance, is often crucial for the optimal antimicrobial therapy of infected patients. Nucleic acid-based assays for the detection of resistance may offer advantages over phenotypic assays. Examples are the detection of the methicillin resistance-encoding mecA gene in staphylococci, rifampin resistance in Mycobacterium tuberculosis, and the spread of resistance determinants across the globe. However, molecular assays for the detection of resistance have a number of limitations. New resistance mechanisms may be missed, and in some cases the number of different genes makes generating an assay too costly to compete with phenotypic assays. In addition, proper quality control for molecular assays poses a problem for many laboratories, and this results in questionable results at best. The development of new molecular techniques, e.g., PCR using molecular beacons and DNA chips, expands the possibilities for monitoring resistance. Although molecular techniques for the detection of antimicrobial resistance clearly are winning a place in routine diagnostics, phenotypic assays are still the method of choice for most resistance determinations. In this review, we describe the applications of molecular techniques for the detection of antimicrobial resistance and the current state of the art

show abstract

Section: Mechanisms Of Resistancementioning

confidence: 99%

Molecular Detection of Antimicrobial Resistance

2001

View full text Add to dashboard Cite

show abstract

“…8) Recent studies demonstrate that preventing podocyte apoptosis may ameliorate renal injury and decrease proteinuria in DN. 9,10) Recent studies have shown that anti-inflammatory and immunomodulatory actions of minocycline are not related to its antimicrobial property. 11) Studies have also suggested a neuroprotective effect of minocycline in experimental models of ischemic stroke, 12) Huntington's disease, 13) Parkinson's disease, 14) traumatic brain injury, 15) amyotropic lateral sclerosis 16) and multiple sclerosis.…”

mentioning

confidence: 99%

Minocycline Attenuates Kidney Injury in a Rat Model of Streptozotocin-Induced Diabetic Nephropathy

Yuan

Zhang

Zheng

et al. 2016

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

The effects of minocycline on the development of diabetic nephropathy (DN) in streptozotocin (STZ) induced diabetic rats were evaluated in this study. The diabetes rats with DN were induced by STZ (55 mg/ kg) injection. The experiment included 5 groups 1) normal, 2) normal plus minocycline for 16 weeks, 3) DN plus vehicle, 4) DN plus minocycline 16 weeks and 5) DN plus minocycline for 8 weeks. The pathological changes were analyzed by hematoxylin and eosin (H&E) staining and the apoptotic cells were stained by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) staining. The mRNA expression of caspase-3, Bax and Bcl-2 in the kidney tissues was detected by quantitative RT-PCR. The biochemical parameters of blood and urine were determined by biochemical analyzer. Treatment with minocycline reduced the urine volume, 24-h urine protein, serum creatinine (Scr), blood urea nitrogen (BUN) but not blood alanine aminotransferase (ALT) in the DN rats. Furthermore, treatment with minocycline improved the pathological score of STZ-injured kidney and reduced the numbers of apoptotic cells in the kidney of DN rats. Moreover, minocycline mitigated the expression of caspase-3 and Bax mRNA, but increased Bcl-2 expression in the kidney of DN rats. These data indicated that minocycline improved the STZ-induced kidney damages, at least partially by protection form long-term hyperglycemia-induced kidney cell apoptosis. Key words minocycline; kidney injury; rat model; diabetic nephropathy (DN)Diabetes mellitus is a complex disease that causes altered glucose homeostasis, 1) and diabetic nephropathy (DN) is the major microvascular complication of diabetes which is prevalent among diabetic patients.2) It is estimated that DN progresses to end-stage renal disease in up to 30% of patients with diabetes. DN is currently the leading cause of end-stage renal disease in most developed societies and is increasingly prevalent in developing countries. The clinical characteristics of DN are progressive urinary albumin excretion and gradual decline of renal function, which results from the multiple pathophysiologic dysfunctions of diabetes. The appearance of microalbuminuria is regarded as the hallmark of DN onset at its early stage, and the continuous existence of albuminuria plays a crucial role in the damage of both renal structure and function. Although the treatment and understanding of DN are progressing, in clinical practice, the strict control of glucose and blood pressure, and the blockade of the renin-angiotensin system can only slow the progression of DN, however, no available therapy can cure DN.The increased urinary albumin excretion is due to the dysfunction of the glomerular barrier, which is considered to be a key target for the prevention and treatment of DN. Among the elementary ingredients of glomeruli structure, the podocyte and its foot process play the pivotal role in maintenance of permselective function of the glomerular barrier. 3)Minocycline is a semi-synthetic derivative of...

show abstract

“…However, few data are currently available to guide clinicians in the optimal use of these agents. The expanded-spectrum tetracyclines doxycycline and minocycline demonstrate excellent oral bioavailability, tissue penetration, and tolerability (14). Published reports on the use of these agents for the treatment of MRSA SSTI suggest their effectiveness but are limited to case studies (2,3,23).…”

mentioning

confidence: 99%

Tetracyclines as an Oral Treatment Option for Patients with Community Onset Skin and Soft Tissue Infections Caused by Methicillin-Resistant Staphylococcus aureus

Ruhe

Menon

2007

Antimicrob Agents Chemother

107

View full text Add to dashboard Cite

Few data exist on the clinical utility of the expanded-spectrum tetracyclines doxycycline and minocycline for the treatment of community-associated methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections (SSTI). We performed a retrospective cohort study of 276 patients who presented with 282 episodes of MRSA SSTI to the emergency room or outpatient clinic at two tertiary medical centers between October 2002 and February 2007. The median percentage of patients infected with MRSA strains that were susceptible to tetracycline was 95%. Time zero was defined as the time of the first incision and drainage procedure or, if none was performed, the time of the first positive wound culture. The median patient age was 48 years. Abscesses constituted the majority of clinical presentations (75%), followed by furuncles or carbuncles (13%) and cellulitis originating from a purulent focus of infection (12%). A total of 225 patients (80%) underwent incision and drainage. Doxycycline or minocycline was administered in 90 episodes (32%); the other 192 SSTI were treated with ␤-lactams. Treatment failure, defined as the need for a second incision and drainage procedure and/or admission to the hospital within at least 2 days after time zero, was diagnosed in 28 episodes (10%) at a median of 3 days after time zero. On logistic regression analysis, receipt of a ␤-lactam agent was the only clinical characteristic associated with treatment failure (adjusted odds ratio, 3.94; 95% confidence interval, 1.28 to 12.15; P ‫؍‬ 0.02). The expanded-spectrum tetracyclines appear to be a reasonable oral treatment option for patients with community onset MRSA SSTI in areas where MRSA strains are susceptible to the tetracyclines.

show abstract

Tetracyclines

Cited by 176 publications

References 35 publications

Molecular Detection of Antimicrobial Resistance

Molecular Detection of Antimicrobial Resistance

Minocycline Attenuates Kidney Injury in a Rat Model of Streptozotocin-Induced Diabetic Nephropathy

Tetracyclines as an Oral Treatment Option for Patients with Community Onset Skin and Soft Tissue Infections Caused by Methicillin-Resistant Staphylococcus aureus

Contact Info

Product

Resources

About